Genelabs Technologies

  • Website:
  • Size: 51-200 employees
  • Overview: Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus, targeting the HCV viral proteins - NS5B polymerase, NS4B, and NS5A. In January 2009 Genelabs was bought by GlaxoSmithKline.

Search 1.5 billion
Email & Phone#

Browse to anyone's Linkedin profile, and Contactout will find that person's email address and phone number

Start your free trial
(300+ Reviews)

People also viewed these companies

  • Education Management
  • Health, Wellness and Fitness
  • Architecture & Planning
  • Marketing and Advertising
  • Health, Wellness and Fitness
  • Construction